Skip to main content
Erschienen in: Current Hematologic Malignancy Reports 4/2017

31.05.2017 | Health Economics (N Khera, Section Editor)

Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities

verfasst von: Abhishek A. Mangaonkar, Mrinal M. Patnaik

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group.

Recent Findings

Elderly AML is a difficult entity to treat due to both disease and patient-related factors. Treatment of this group has a lot of inter-physician and inter-institutional variability. Several objective criteria to assess biological age, impact of co-morbidities, and fitness have been published, which could be utilized to make management decisions. For old and unfit AML patients, a variety of novel therapeutic agents are currently being investigated.

Summary

Objective analysis of biological age should include assessment of fitness, frailty, and co-morbidities in elderly AML. Future areas of research include development of an objective risk-based approach and its validation in clinical trials, development of novel therapeutic agents, and improvement in supportive care measures.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, et al. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29(6):1312–9. doi:10.1038/leu.2015.38.CrossRefPubMed Burnett AK, Russell N, Hills RK, Panoskaltsis N, Khwaja A, Hemmaway C, et al. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29(6):1312–9. doi:10.​1038/​leu.​2015.​38.CrossRefPubMed
3.
Zurück zum Zitat Foran JM, Sun Z, Claxton DF, Lazarus HM, Thomas ML, Melnick A, et al. North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood. 2015;126(23):217. Foran JM, Sun Z, Claxton DF, Lazarus HM, Thomas ML, Melnick A, et al. North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN Cancer Research Group (E2906). Blood. 2015;126(23):217.
4.
Zurück zum Zitat Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98(3):548–53.CrossRefPubMed Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman PP, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood. 2001;98(3):548–53.CrossRefPubMed
8.
Zurück zum Zitat Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000–8. doi:10.1016/s0140-6736(10)62105-8.CrossRefPubMed Krug U, Rollig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet. 2010;376(9757):2000–8. doi:10.​1016/​s0140-6736(10)62105-8.CrossRefPubMed
10.
Zurück zum Zitat Mohamed I, Hills RK, Burnett AK. Who is an “older” patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials. Br J Haematol. 2014;165(1):147–51. doi:10.1111/bjh.12705.CrossRefPubMed Mohamed I, Hills RK, Burnett AK. Who is an “older” patient with acute myeloid leukaemia (AML)? An investigation of two NCRI/AML trials. Br J Haematol. 2014;165(1):147–51. doi:10.​1111/​bjh.​12705.CrossRefPubMed
12.
Zurück zum Zitat Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417–23. doi:10.1200/jco.2011.35.7525.CrossRefPubMedPubMedCentral Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417–23. doi:10.​1200/​jco.​2011.​35.​7525.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. doi:10.1182/blood-2008-07-172007.CrossRefPubMed Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179–87. doi:10.​1182/​blood-2008-07-172007.CrossRefPubMed
14.
Zurück zum Zitat Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597–603.CrossRefPubMed Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162(14):1597–603.CrossRefPubMed
15.
Zurück zum Zitat Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9. doi:10.1200/jco.2009.23.8329.CrossRefPubMed Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562–9. doi:10.​1200/​jco.​2009.​23.​8329.CrossRefPubMed
16.
Zurück zum Zitat Stein RS, Vogler WR, Winton EF, Cohen HJ, Raney MR, Bartolucci A. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. Leuk Res. 1990;14(10):895–903.CrossRefPubMed Stein RS, Vogler WR, Winton EF, Cohen HJ, Raney MR, Bartolucci A. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. Leuk Res. 1990;14(10):895–903.CrossRefPubMed
17.
Zurück zum Zitat Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(33):5580–6. doi:10.1200/jco.2009.22.2547.CrossRefPubMed Rao AV, Valk PJ, Metzeler KH, Acharya CR, Tuchman SA, Stevenson MM, et al. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia. J Clin Oncol. 2009;27(33):5580–6. doi:10.​1200/​jco.​2009.​22.​2547.CrossRefPubMed
18.
Zurück zum Zitat Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 1999;94(3):1046–56.PubMed Legrand O, Simonin G, Beauchamp-Nicoud A, Zittoun R, Marie JP. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 1999;94(3):1046–56.PubMed
19.
Zurück zum Zitat Garrido SM, Cooper JJ, Appelbaum FR, Willman CL, Kopecky K, Banker DE. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res. 2001;25(1):23–32.CrossRefPubMed Garrido SM, Cooper JJ, Appelbaum FR, Willman CL, Kopecky K, Banker DE. Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis. Leuk Res. 2001;25(1):23–32.CrossRefPubMed
20.
Zurück zum Zitat Prebet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747–53. doi:10.1200/jco.2008.21.0674.CrossRefPubMed Prebet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol. 2009;27(28):4747–53. doi:10.​1200/​jco.​2008.​21.​0674.CrossRefPubMed
21.
Zurück zum Zitat Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18(4):809–16. doi:10.1038/sj.leu.2403289.CrossRefPubMed Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004;18(4):809–16. doi:10.​1038/​sj.​leu.​2403289.CrossRefPubMed
23.
Zurück zum Zitat Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208–16. doi:10.3324/haematol.2012.067892.CrossRefPubMedPubMedCentral Deschler B, Ihorst G, Platzbecker U, Germing U, Marz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98(2):208–16. doi:10.​3324/​haematol.​2012.​067892.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16(3):872–81. doi:10.1200/jco.1998.16.3.872.CrossRefPubMed Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16(3):872–81. doi:10.​1200/​jco.​1998.​16.​3.​872.CrossRefPubMed
25.
Zurück zum Zitat Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–11.CrossRefPubMed Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1302–11.CrossRefPubMed
26.
Zurück zum Zitat Wetzler M, Mrozek K, Kohlschmidt J, Dombret H, Dohner H, Pilorge S, et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014;99(2):308–13. doi:10.3324/haematol.2013.092072.CrossRefPubMedPubMedCentral Wetzler M, Mrozek K, Kohlschmidt J, Dombret H, Dohner H, Pilorge S, et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014;99(2):308–13. doi:10.​3324/​haematol.​2013.​092072.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–7. doi:10.1200/jco.2011.38.9429.CrossRefPubMedPubMedCentral Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–7. doi:10.​1200/​jco.​2011.​38.​9429.CrossRefPubMedPubMedCentral
30.
32.
33.
Zurück zum Zitat Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83. doi:10.1001/jama.2011.1558.CrossRefPubMedPubMedCentral Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA. 2011;306(17):1874–83. doi:10.​1001/​jama.​2011.​1558.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, et al. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant. 2012;47(4):494–8. doi:10.1038/bmt.2011.114.CrossRefPubMed Majhail NS, Brunstein CG, Shanley R, Sandhu K, McClune B, Oran B, et al. Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors. Bone Marrow Transplant. 2012;47(4):494–8. doi:10.​1038/​bmt.​2011.​114.CrossRefPubMed
35.
Zurück zum Zitat Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant. 2012;18(2):289–94. doi:10.1016/j.bbmt.2011.07.013.CrossRefPubMed Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, et al. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant. 2012;18(2):289–94. doi:10.​1016/​j.​bbmt.​2011.​07.​013.CrossRefPubMed
36.
Zurück zum Zitat Koreth J, Aldridge J, Kim HT, Alyea EP 3rd, Cutler C, Armand P, et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010;16(6):792–800. doi:10.1016/j.bbmt.2009.12.537.CrossRefPubMedPubMedCentral Koreth J, Aldridge J, Kim HT, Alyea EP 3rd, Cutler C, Armand P, et al. Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010;16(6):792–800. doi:10.​1016/​j.​bbmt.​2009.​12.​537.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. doi:10.1001/jama.2009.813.CrossRefPubMedPubMedCentral Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. doi:10.​1001/​jama.​2009.​813.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, et al. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: a Center for International Blood and Marrow Transplant Research cohort analysis. Cancer. 2017; doi:10.1002/cncr.30567. Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, et al. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: a Center for International Blood and Marrow Transplant Research cohort analysis. Cancer. 2017; doi:10.​1002/​cncr.​30567.
39.
Zurück zum Zitat Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104(4):961–8. doi:10.1182/blood-2004-02-0545.CrossRefPubMed Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104(4):961–8. doi:10.​1182/​blood-2004-02-0545.CrossRefPubMed
41.
Zurück zum Zitat Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.CrossRefPubMed Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.CrossRefPubMed
45.
Zurück zum Zitat Medeiros BC, Lancet JE, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. Analysis of efficacy by age for patients aged 60-75 with untreated secondary acute myeloid leukemia (AML) treated with CPX-351 liposome injection versus conventional cytarabine and daunorubicin in a phase III trial. Blood. 2016;128(22):902. Medeiros BC, Lancet JE, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. Analysis of efficacy by age for patients aged 60-75 with untreated secondary acute myeloid leukemia (AML) treated with CPX-351 liposome injection versus conventional cytarabine and daunorubicin in a phase III trial. Blood. 2016;128(22):902.
46.
Zurück zum Zitat Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025–36. doi:10.1016/s1470-2045(15)00201-6.CrossRefPubMedPubMedCentral Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2015;16(9):1025–36. doi:10.​1016/​s1470-2045(15)00201-6.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Daver N. Long term survival and clinical complete responses of various prognostic subgroups in 103 relapsed/refractory acute myeloid leukemia (r/r AML) patients treated with guadecitabine (SGI-110). Blood. 2016. Daver N. Long term survival and clinical complete responses of various prognostic subgroups in 103 relapsed/refractory acute myeloid leukemia (r/r AML) patients treated with guadecitabine (SGI-110). Blood. 2016.
48.
Zurück zum Zitat Eytan M. Stein JKA, Robert Collins, Daniel J DeAngelo, Amir T Fathi, Ian Flinn et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies (Abstract). Blood. 2014;2014(124:115). Eytan M. Stein JKA, Robert Collins, Daniel J DeAngelo, Amir T Fathi, Ian Flinn et al. AG-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant metabolic enzyme, induces durable remissions in a phase I study in patients with IDH2 mutation positive advanced hematologic malignancies (Abstract). Blood. 2014;2014(124:115).
49.
Zurück zum Zitat Stéphane de Botton DAP, Eytan M Stein, Courtney DiNardo, Amir T Fathi, Gail J Roboz, Robert Collins, Ronan T Swords, Ian Flinn, Jessica K Altman, Martin S Tallman, Hagop Kantarjian, Katelyn Colby, Bin Fan, Meredith Goldwasser, Malia Prahl, Sam Agresta, Richard M Stone. Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH-1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies. EHA abstract. 2015. Stéphane de Botton DAP, Eytan M Stein, Courtney DiNardo, Amir T Fathi, Gail J Roboz, Robert Collins, Ronan T Swords, Ian Flinn, Jessica K Altman, Martin S Tallman, Hagop Kantarjian, Katelyn Colby, Bin Fan, Meredith Goldwasser, Malia Prahl, Sam Agresta, Richard M Stone. Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH-1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies. EHA abstract. 2015.
51.
Zurück zum Zitat Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood. 2012;120(21):48. Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P, et al. Final results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients ≥ 60 years of age with FLT3 ITD positive or negative relapsed/refractory acute myeloid leukemia. Blood. 2012;120(21):48.
52.
Zurück zum Zitat Uy GL, Mandrekar S, Laumann K, Sanford B, Marcucci G, Zhao W, et al. Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (alliance C11001). Blood. 2015;126(23):319. Uy GL, Mandrekar S, Laumann K, Sanford B, Marcucci G, Zhao W, et al. Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (alliance C11001). Blood. 2015;126(23):319.
53.
Zurück zum Zitat Bixby DL, Stein AS, Fathi AT, Kovacsovics TJ, Levy MY, Erba HP, et al. Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML). Blood. 2016;128(22):590. Bixby DL, Stein AS, Fathi AT, Kovacsovics TJ, Levy MY, Erba HP, et al. Vadastuximab talirine monotherapy in older patients with treatment naive CD33-positive acute myeloid leukemia (AML). Blood. 2016;128(22):590.
54.
Zurück zum Zitat Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, et al. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017; doi:10.1038/leu.2017.85. Montalban-Bravo G, Huang X, Naqvi K, Jabbour E, Borthakur G, DiNardo CD, et al. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia. 2017; doi:10.​1038/​leu.​2017.​85.
Metadaten
Titel
Patterns of Care and Survival for Elderly Acute Myeloid Leukemia—Challenges and Opportunities
verfasst von
Abhishek A. Mangaonkar
Mrinal M. Patnaik
Publikationsdatum
31.05.2017
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 4/2017
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-017-0388-8

Weitere Artikel der Ausgabe 4/2017

Current Hematologic Malignancy Reports 4/2017 Zur Ausgabe

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (D Persky, Section Editor)

Therapeutic Options for Aggressive T-Cell Lymphomas

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.